Compare Crowdstrike Holdings Inc (CRWD) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crowdstrike Holdings Inc vs Smith & Nephew plc — how do they compare? Crowdstrike Holdings Inc trades at $275.04 (market cap $269.31B), while Smith & Nephew plc trades at $27.24 (market cap $11.10B). The key difference: Crowdstrike Holdings Inc is far larger — about 24.3× Smith & Nephew plc's market cap, and Smith & Nephew plc pays a 2.95% dividend while Crowdstrike Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crowdstrike Holdings Inc for 97 Days and Smith & Nephew plc for 121 Days on average.
| CRWD | SNN | |
|---|---|---|
Market Cap | $269.31B | $11.10B |
Volume | 9,381,560 | 1,051,703 |
Sector | Technology | Health |
52-Week High | $278.86 | $37.17 |
52-Week Low | $87.56 | $26.42 |
Typical Hold Time | 97 Days | 121 Days |
Enterprise Value | $265.11B | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CrowdStrike (CRWD) trades at $263.01, down 0.92% today but near its 52-week high. The stock shows strong technical momentum with bullish moving averages and recent earnings beats. Revenue growth remains robust at $3.95B for 2025, though profitability is challenged with a net margin of -0.49%. Analyst sentiment is overwhelmingly positive with 76% buy ratings and a $239.38 consensus target, while recent news highlights AI-driven cybersecurity demand as a key growth catalyst.
Outlook remains favorable given CrowdStrike's leadership in AI-native cybersecurity and expanding market opportunities. However, elevated valuation multiples (P/S 49.86) and competitive pressures present risks. The stock's proximity to all-time highs suggests near-term consolidation potential, but long-term growth prospects in cybersecurity remain compelling.
SNN trades at $26.96, up 0.26% on the day, but near its 52-week low amid a bearish technical signal. Recent earnings have mostly beaten expectations, with Q2 2026 EPS of $0.946 exceeding the $0.939 estimate. Revenue grew to $6.16B in 2025, and net income margin improved to 10.08%. The company continues to launch new medical products, such as the EVOS PELVIC System, to drive growth.
The outlook is mixed; strong fundamentals and product innovation support long-term value, but near-term price pressure and analyst caution pose risks. Investors should weigh robust profitability against competitive threats and recent management changes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crowdstrike Holdings Inc
CrowdStrike Holdings provides cybersecurity products and services aimed at protecting organizations from cyberthreats. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, identity protection, and log management. CrowdStrike went public in 2019 and serves customers worldwide.
Read more on CRWD →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
